Daaweynta CAR-T ee Kansarka Caloosha

Claudin18.2 (CLDN18.2) waa borotiin isku xiran oo si gaar ah loogu muujiyo epithelium-ka caloosha iyo si aad ah loogu muujiyo dusha sare ee unugyada kansarka caloosha. CT041 (koodka horumarinta CG4006) waa badeeco CAR-T ah oo iskeed u shaqeysa oo bartilmaameedsanaysa CLDN18.2. Xogta Marxaladda I waxay muujinaysaa firfircooni ka hortag ah oo rajo leh oo ku saabsan bukaanada kansarka caloosha ee si weyn loo daaweeyay, CLDN18.2-positive.

HER2 oo aad u daran ayaa sidoo kale lagu arkaa qayb ka mid ah bukaanada kansarka caloosha. Daaweynta CAR-T ee HER2 ee bartilmaameedsanaysa waxay muujisay awood ka-hortagga burooyinka daraasadaha kahor kiliinikada iyo kuwa hore ee kiliinikada. TAC01-HER2 ee Triumvira Immunologics hadda waxay ku jirtaa tijaabooyinka kiliinikada ee Wajiga II.

• Bartilmaameed Aad u Gaar ah: Marka unugyada CAR-T lagu hago CLDN18.2 ama HER2, unugyada kansarka caloosha si sax ah ayaa loo aqoonsan karaa oo loo baabi'in karaa, taasoo yaraynaysa saameynta burooyinka ka baxsan.

• Ka Gudubka Iska caabinta Daaweynta MultilineTijaabooyinka CT041, kooxda kansarka caloosha waxay gaareen heer jawaab celin ah oo ujeedo leh (ORR) oo ah 57.1%, heerka xakamaynta cudurrada (DCR) oo ah 75.0%, iyo badbaadada guud ee 6 bilood (OS) oo ah 81.2% bukaannada ku guuldareystay dhowr daaweyn oo hore.

• Jawaabaha WaaraDaawaynta CLDN18.2-CAR-T waxay keentay heer jawaab celin ah oo 6 bilood ah oo ah 44.8%, taasoo soo jeedinaysa suurtagalnimada faa'iido caafimaad oo muddo dheer ah.

• Daaweynta Shakhsi ahaaneedIsticmaalka unugyada T ee bukaanka waxay yareysaa khatarta ah in la diido waxayna kor u qaaddaa badbaadada iyo waxtarka.

• Ururinta Unugyada T-ga Dhiigga ee Dusha sare
  Unugyada T-ga waxaa laga soocaa dhiigga bukaanka iyada oo loo marayo leukapheresis.

• Injineernimada Hiddaha
  Shaybaar u hoggaansan GMP, unugyada T waxaa loo beddelaa si ay u muujiyaan CAR bartilmaameedsanaya CLDN18.2 ama HER2, ka dibna la ballaariyo ex vivo.

• Xaaladda Qanjirka 'Lymphodepleting'
  Nidaam diyaarin ah oo ah cyclophosphamide iyo fludarabine ayaa la maamulaa si loo yareeyo lymphocytes-ka gudaha jirka loona abuuro meel wanaagsan oo loogu talagalay fidinta unugyada CAR-T.

• Faleebo Unugga CAR-T
  Unugyada CAR-T ee la farsameeyay ayaa dib loogu shubaa bukaanka iyadoo xididka la gelinayo.

• La socodka iyo Maareynta
  Ka dib marka la geliyo daawada, bukaanada waxaa si dhow loola socdaa cudurka sii deynta cytokine (CRS) iyo sunta neerfaha, iyadoo la adeegsanayo waxqabadyo waqtigooda ku habboon haddii loo baahdo.

• Falanqaynta Ku-meel-gaarka ah ee Wejiga 1aad ee CT041 (CLDN18.2-CAR-T)
  37 bukaan oo si aad ah loo daaweeyay, kooxda kansarka caloosha ayaa gaartay ORR 57.1%, DCR 75.0%; 94.6% waxay la kulmeen oo keliya CRS-ka Heerka 1-2, iyadoo aan lahayn CRS ama sunta neerfaha ee Heerka 3 ama ka sareeya; muddada 6-bilood ee jawaab celinta waxay ahayd 44.8%.

• Satri-cel (sidoo kale bartilmaameedsanaya CLDN18.2) Natiijooyinka kama dambaysta ah ee wejiga I
  98 bukaan oo qaba kansarka caloosha iyo mindhicirka ee CLDN18.2-positive, ORR wuxuu ahaa 38.8%, DCR 91.8%; badbaadada dhexdhexaadka ah ee aan horumarka lahayn (mPFS) waxay ahayd 4.4 bilood (95% CI 3.7–6.6), badbaadada guud ee dhexdhexaadka ah (mOS) 8.8 bilood (95% CI 7.1–10.2); 96.9% waxay la kulmeen oo keliya CRS-ka Heerka 1–2, iyadoo aan lahayn CRS-ka Heerka 3+ ama dhimasho la xiriirta.

• Xogta Caafimaad ee Hore ee HER2-CAR-T
  Daraasaddii ugu horreysay ee Wejiga 1aad ee aadanaha waxay muujisay muuqaal badbaado oo la maarayn karo; tijaabo diiwaangelin Wajiga II ayaa socota.

• Madal Tiknoolajiyadeed oo Horseed ah
  BIOOCUS waxay maamushaa xarun caalami ah oo lagu sameeyo daaweynta unugyada heerka GMP, iyadoo hubinaysa wax soo saarka unugyada CAR-T oo hufan oo joogto ah.

• Kooxda Khabiirada ee Xirfado badan leh
  Kooxdayadu waxay ka kooban tahay khabiiro khibrad u leh difaaca jirka, kansarka, iyo daaweynta unugyada, iyagoo bixinaya maareyn shaqsiyeed oo dhammaystiran.

• Waayo-aragnimada Caafimaadka Caalamiga ah
  Waxaan daweynay bukaanada ka kala yimid daafaha dunida, annagoo ururinayna xog ballaaran oo ku saabsan badbaadada iyo waxtarka.

• Adeeg Dhammaad-ilaa-Dhammaad ah
  Laga bilaabo naqshadeynta hab-maamuuska iyo isku-dubaridka daaweynta dibadda ilaa dabagalka muddada dheer ee tallaalka kadib, BIOOCUS waxay bixisaa taageero hal joogsi ah.